Day: April 21, 2026

ROHM Develops Latest Device of its EcoSiC™ Series:The 5th generation SiC MOSFETs optimized for high-efficiency power applications.Reducing On-Resistance at High Temperatures Compared to Conventional 4th Generation ProductsContributes to making units smaller while increasing output power in high temperature applications.Santa Clara, CA and Kyoto, Japan, April 21, 2026 (GLOBE NEWSWIRE) — ROHM Semiconductor today announced it has developed the latest device of its EcoSiC™ series: the 5th Generation SiC MOSFETs optimized for high‑efficiency power applications. This technology is ideally suitable for automotive electric powertrain systems – such as traction inverters for electric vehicles (xEVs) – as well as power supplies for AI servers and industrial equipment such as data centers. In recent years, the...

Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with low FAP expression and more favorable kinetic profile compared to the marketed antibody-drug conjugate (ADC) Enhertu® Dual payload capability of the pre|CISION platform showcased with first in vivo exposure and efficacy data LONDON and PHILADELPHIA, April 21, 2026 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is giving two presentations today at the American Association for Cancer Research (AACR) Annual Meeting 2026.  These presentations include the first in vivo efficacy and exposure pharmacology for the pre|CISION® dual payload technology program and updated...

21 April 2026 Disclosure of trading in own shares under a share buyback program Period: From 13 to 17 April 2026 Issuer’s registered name: Ipsos Issuer’s Identification code: 9695002OY2X35E9X8W87 Financial instrument reference: Ordinary shares – ISIN code FR0000073298 Reporting of transactions in aggregated form (per day and per trading venue)Issuer name Issuer Code Transaction date ISIN Code Daily total volume (in number of shares) Daily weighted average price of shares acquired Platform      ISIN code (ISO 6166)     MIC code (ISO 10383)IPSOS 9695002OY2X35E9X8W87 13-Apr-26 FR0000073298 15 500 36,1261 XPARIPSOS 9695002OY2X35E9X8W87 13-Apr-26 FR0000073298 10 777 36,0545 DXEIPSOS 9695002OY2X35E9X8W87 13-Apr-26 FR0000073298 959 36,0840 TQEIPSOS 9695002OY2X35E9X8W87 13-Apr-26 FR0000073298 1 492 36,0964 AQEIPSOS 9695002OY2X35E9X8W87 14-Apr-26 FR0000073298 16...

                 CENERGY HOLDINGS SA30 Avenue Marnix, 1000 Brussels, Belgium0649.991.654 RLE (Brussels) CONVENING NOTICE TO ATTEND THE ANNUAL ORDINARY SHAREHOLDERS’MEETING TO BE HELD ON 26 MAY 2026 The board of directors of Cenergy Holdings SA (the Company) (the Board of Directors) invites the shareholders to participate to the annual ordinary shareholders’ meeting (the Meeting) to be held on Tuesday, 26 May 2026 at 10.00 a.m. CET at its registered offices, 30 Avenue Marnix, 1000, Brussels, Belgium. AGENDA OF THE MEETINGManagement report of the Board of Directors on the annual accounts of the Company for the accounting year ended 31 December 2025. Report of the statutory auditor on the annual accounts of the Company for the accounting year ended 31 December 2025. Presentation of the consolidated financial statements, the management...

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that detailed results from the global, randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) will be presented in a Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago. Revolution Medicines recently reported an unprecedented overall survival (OS) benefit with daraxonrasib from the RASolute 302 clinical trial. These topline results showed that daraxonrasib taken once daily orally met all primary and key secondary endpoints, demonstrating...

First-year Targets: 20-40 Agents Live, 10-15% Efficiency Gains Axelle de Faÿ Appointed Chief Customer Experience Officer, Unifying Every Customer Touchpoint with Agentic AI Frédéric Dupont-Aldiolan Named Chief Human Resources Officer, Architecting a Workforce Augmented by AI Sidetrade (Euronext Growth: ALBFR.PA), the AI-native Order-to-Cash company, today announces two senior leadership appointments as it executes O2C Intelligence 2030, its strategic plan to operate as an AI-native enterprise. Axelle de Faÿ joins as Chief Customer Experience Officer and Frédéric Dupont-Aldiolan is appointed Chief Human Resources Officer. These appointments position the Group for an operating model where every employee works alongside AI agents. McKinsey’s State of Organizations 2026 survey finds that while 88% of organizations are now deploying AI...

Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBMCAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026, in Chicago. Details for the Oral Presentation: Session Type/Title: Rapid Oral Abstract Session – Lung Cancer—Non-Small Cell MetastaticTitle: Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535)...

(2026-04-21) Kitron has secured an order valued at approximately EUR 37 million for the production and supply of advanced radio systems used in tactical mobile platforms. Delivery of the order is scheduled to begin in first half of 2027, and production will take place at one of Kitron’s European facilities. “Next-generation tactical communications are becoming a core pillar of modern defence programs. This contract strengthens Kitron’s trajectory in high-complexity RF systems and underlines our ability to scale with growing European and allied demand. We are proud to continue our role as a trusted test-development and manufacturing partner.” says Hans Petter Thomassen, Vice President Nordics and North America, Kitron. As defence programs expand, resilience in the electronics supply chain is becoming decisive. This contract shows how Kitron’s...